Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas

[1]  M. Lai,et al.  Hepatitis C virus induces a mutator phenotype: Enhanced mutations of immunoglobulin and protooncogenes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  V. Pitini,et al.  Systematic screening for HCV infection should be performed in patients with splenic marginal zone lymphoma , 2004, British journal of haematology.

[3]  C. Pascutto,et al.  Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles , 2004, Cancer.

[4]  M. Lai,et al.  Treatment of HCV-related mantle-cell lymphoma with ribavirin and pegylated interferon Alfa. , 2003, The New England journal of medicine.

[5]  P. Caini,et al.  Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. , 2003, Blood.

[6]  S. Franceschi,et al.  Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. , 2003, Blood.

[7]  T. Loughran,et al.  Antigen-driven clonal T cell expansion in disorders of hematopoiesis. , 2003, Leukemia research.

[8]  J. Dierlamm.  Genetic abnormalities in marginal zone B-cell lymphoma. , 2003, Haematologica.

[9]  H. El‐Serag,et al.  Extrahepatic manifestations of hepatitis C among United States male veterans , 2002, Hepatology.

[10]  P. Caini,et al.  Prevalence of bcl-2 Rearrangement in Patients with Hepatitis C VirusRelated Mixed Cryoglobulinemia with or without B-Cell Lymphomas , 2002, Annals of Internal Medicine.

[11]  Takeshi Tokuhisa,et al.  Activation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation , 2002, The Journal of experimental medicine.

[12]  X. Mariette,et al.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. , 2002, The New England journal of medicine.

[13]  W. Wright,et al.  Prospective study of hepatitis C viral infection as a risk factor for subsequent B-cell neoplasia. , 2002, Blood.

[14]  C. Mecucci,et al.  Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. , 2002, Blood.

[15]  A. Campos-Caro,et al.  Persistent polyclonal B lymphocytosis: an expansion of cells showing IgVH gene mutations and phenotypic features of normal lymphocytes from the CD27+ marginal zone B‐cell compartment , 2002, British journal of haematology.

[16]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[17]  S. Levy,et al.  The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. , 2001, Blood.

[18]  Y. Sterkers,et al.  Hepatitis C virus infection and lymphoproliferative diseases: Prospective study on 1,576 patients in France , 2001, American journal of hematology.

[19]  R. Marasca,et al.  Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. , 2001, The American journal of pathology.

[20]  D. Yeshurun,et al.  The effect of antiviral therapy on t ( 14 ; 18 ) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection , 2001 .

[21]  S. Levy,et al.  V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. , 2001, Blood.

[22]  D. Yeshurun,et al.  bcl‐2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection , 2001, British journal of haematology.

[23]  J. Turkson,et al.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.

[24]  A. Carbone,et al.  Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. , 2000, Blood.

[25]  A. Carbone,et al.  Pre‐malignant and malignant lymphoproliferations in an HCV‐infected type II mixed cryoglobulinemic patient are sequential phases of an antigen‐driven pathological process , 2000, International journal of cancer.

[26]  E. Macintyre,et al.  Rapid, multifluorescent TCRG Vγ and Jγ typing: application to T cell acute lymphoblastic leukemia and to the detection of minor clonal populations , 2000, Leukemia.

[27]  G. Salles,et al.  Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. , 2000, Blood.

[28]  B. Arnulf,et al.  Rapid, multifluorescent TCRG Vgamma and Jgamma typing: application to T cell acute lymphoblastic leukemia and to the detection of minor clonal populations. , 2000, Leukemia.

[29]  G. Salles,et al.  Distinct chromosome 3 abnormalities in persistent polyclonal B‐cell lymphocytosis , 1999, Genes, Chromosomes and Cancer.

[30]  F. Shepherd,et al.  No association between hepatitis C and B‐cell lymphoma , 1999, Hepatology.

[31]  Hepatitis C virus infection in patients with overt B-cell non-Hodgkin's lymphoma in a French center. , 1999, Blood.

[32]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[33]  M. Luppi,et al.  Hepatitis C Virus Genotype Distribution in B-Cell Non-Hodgkin Lymphoma , 1998, Annals of Internal Medicine.

[34]  P. King,et al.  Hepatitis C virus infection in non-Hodgkin's lymphoma. , 1998, Clinical and laboratory haematology.

[35]  D. Sansonno,et al.  Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. , 1998, Journal of immunology.

[36]  O. Burrone,et al.  Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. , 1998, Blood.

[37]  D. Michel,et al.  HCV and HGV in B-cell non-Hodgkin's lymphoma. , 1998, Journal of hepatology.

[38]  L. Pucillo,et al.  Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. , 1997, Blood.

[39]  B. Nathwani,et al.  Hepatitis C Virus Infection in Patients with B-Cell Non-Hodgkin Lymphoma , 1997, Annals of Internal Medicine.

[40]  Y. Miura,et al.  B cell malignancy and hepatitis C virus infection. , 1997, Leukemia.

[41]  R. Tait,et al.  The role of hepatitis C virus in the aetiology of non-Hodgkins lymphoma--a regional association? , 1997, Leukemia & lymphoma.

[42]  C. Ferri,et al.  Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma: evidence for a pathogenetic role , 1997, Archives of Virology.

[43]  S. Monfardini,et al.  Hepatitis C virus and non‐Hodgkin's lymphomas , 1996, British journal of haematology.

[44]  R. Marasca,et al.  Additional neoplasms and HCV infection in low‐grade lymphoma of MALT type , 1996, British journal of haematology.

[45]  C. Mazzaro,et al.  Regression of monoclonal B‐cell expansion in patients affected by mixed cryoglobulinemia responsive to α‐interferon therapy , 1996, Cancer.

[46]  R. Fanin,et al.  Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. , 1996, Blood.

[47]  R. Marasca,et al.  Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. , 1996, Leukemia.

[48]  E. Macintyre,et al.  Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients. , 1995, Blood.

[49]  G. Pasero,et al.  Hepatitis C virus infection in patients with non‐Hodgkin's lymphoma , 1994, British journal of haematology.

[50]  D. Kabelitz,et al.  Immunological studies of γδ T cells in a case of large granular lymphocyte -LGL) leukemia : leukemic γδ+ T cells are resistant to growth stimulation in vitro but respond to interferon-α treatment in vivo , 1992 .

[51]  D. Kabelitz,et al.  Immunological studies of gamma delta T cells in a case of large granular lymphocyte (LGL) leukemia: leukemic gamma delta+ T cells are resistant to growth stimulation in vitro but respond to interferon-alpha treatment in vivo. , 1992, Leukemia research.

[52]  M. Alper.  Lymphoproliferative Disorders , 1996, Journal of clinical neuro-ophthalmology.

[53]  C. Riccardi,et al.  Limiting dilution analysis of the frequency of human T cells and large granular lymphocytes proliferating in response to interleukin 2. II. Regulatory role of interferon on proliferative and cytotoxic precursors. , 1983, Journal of immunology.